Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 22;14(5):954.
doi: 10.3390/genes14050954.

Metabolic Myopathies in the Era of Next-Generation Sequencing

Jon Andoni Urtizberea  1 , Gianmarco Severa  2   3 , Edoardo Malfatti  3
Affiliations
Review

Metabolic Myopathies in the Era of Next-Generation Sequencing

Jon Andoni Urtizberea et al. Genes (Basel). .

Abstract

Metabolic myopathies are rare inherited disorders that deserve more attention from neurologists and pediatricians. Pompe disease and McArdle disease represent some of the most common diseases in clinical practice; however, other less common diseases are now better-known. In general the pathophysiology of metabolic myopathies needs to be better understood. Thanks to the advent of next-generation sequencing (NGS), genetic testing has replaced more invasive investigations and sophisticated enzymatic assays to reach a final diagnosis in many cases. The current diagnostic algorithms for metabolic myopathies have integrated this paradigm shift and restrict invasive investigations for complicated cases. Moreover, NGS contributes to the discovery of novel genes and proteins, providing new insights into muscle metabolism and pathophysiology. More importantly, a growing number of these conditions are amenable to therapeutic approaches such as diets of different kinds, exercise training protocols, and enzyme replacement therapy or gene therapy. Prevention and management-notably of rhabdomyolysis-are key to avoiding serious and potentially life-threatening complications and improving patients' quality of life. Although not devoid of limitations, the newborn screening programs that are currently mushrooming across the globe show that early intervention in metabolic myopathies is a key factor for better therapeutic efficacy and long-term prognosis. As a whole NGS has largely increased the diagnostic yield of metabolic myopathies, but more invasive but classical investigations are still critical when the genetic diagnosis is unclear or when it comes to optimizing the follow-up and care of these muscular disorders.

Keywords: Cori–Forbes disease; McArdle disease; Pompe disease; TK2 myopathy; Tarui disease; glycogen storage disorders; lipid storage diseases; metabolic myopathies; mitochondrial myopathies; muscle glycogenoses; muscle metabolism; polyglucosan body myopathies.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose that might be related to this paper.

Figures

Figure 1
Figure 1
Metabolic pathways and corresponding metabolic myopahties. Created with BioRender.com (https://www.biorender.com/ accessed on 4 April 2023).
Figure 2
Figure 2
Clinical symptoms and/or signs highly suggestive of metabolic myopathies. Font size depends on the frequency of the element in the specific group. The highlighted features are found only in the group they belong to (created with BioRender.com, https://www.biorender.com/ accessed on 4 April 2023).
Figure 3
Figure 3
Biomarkers in metabolic myopathies. “ ** ” in patients with CPT II, hyperCKemia is frequent during fasting. “ * ” 10–15% of patient with mitochondrial myopathies can present abnormalities in urine organic acids level.
Figure 4
Figure 4
A semplified diagnostic algorithm for metabolic myopathies. Created with BioRender.com.
See this image and copyright information in PMC

References

    1. Tarnopolsky M.A. Metabolic Myopathies. Contin. Lifelong Learn. Neurol. 2016;22:1829–1851. doi: 10.1212/CON.0000000000000403. - DOI - PubMed
    1. Angelini C., Marozzo R., Pegoraro V., Sacconi S. Diagnostic challenges in metabolic myopathies. Expert Rev. Neurother. 2020;20:1287–1298. doi: 10.1080/14737175.2020.1825943. - DOI - PubMed
    1. Parikh S., Goldstein A., Koenig M.K., Scaglia F., Enns G.M., Saneto R., Anselm I., Cohen B.H., Falk M.J., Greene C., et al. Diagnosis and management of mitochondrial disease: A consensus statement from the Mitochondrial Medicine Society. Anesthesia Analg. 2014;17:689–701. doi: 10.1038/gim.2014.177. - DOI - PMC - PubMed
    1. Guémy C., Laforêt P. The new horizons for treatment of Late-Onset Pompe Disease (LOPD) Rev. Neurol. 2023;179:81–89. doi: 10.1016/j.neurol.2022.12.004. - DOI - PubMed
    1. Byrne B., Bratkovic D., Díaz-Manera J., Laforêt P., Mozaffar T., van der Ploeg A., Roberts M., Schoser B., Toscano A., Jiang H., et al. Cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease (LOPD): PROPEL study subgroup analyses. Mol. Genet. Metab. 2022;135:S27–S28. doi: 10.1016/j.ymgme.2021.11.054. - DOI

MeSH terms